Assessment of the Prognostic Role of HER2 Overexpression in Patients with Node-Negative, pT1a-b Breast Cancer

Updated Survival Analysis of the EGF104900 Randomized Study of Lapatinib Alone or Combined with Trastuzumab for HER2-Positive Breast Cancer Progressing on Trastuzumab

Molecular Characterization of Breast Cancer Core Biopsy Specimens by RT-PCR Gene Expression Analysis

Effect of a 21-Gene RT-PCR Assay on Treatment Recommendations for Patients with Node-Positive, ER-Positive Breast Cancer

Prognostic and Predictive Value of the 21-Gene Recurrence Score^® for Women with Node-Positive Breast Cancer Receiving Chemotherapy

Tyrosine Kinases as Targets for Cancer Therapy

Sunitinib versus Capecitabine for Patients with HER2-Negative Advanced Breast Cancer

SOLTI-0701 — A Double-Blind, Randomized Phase IIb Study of Capecitabine with or without Sorafenib in Advanced Breast Cancer

Double-Blind, Randomized Phase IIb Study of Paclitaxel with or without Sorafenib for Patients with HER2-Negative Advanced Breast Cancer

Analysis of the Incidence of Osteonecrosis of the Jaw and Surgical Complications with Neoadjuvant Therapy in Patients Receiving Bevacizumab

AVADO — Final Overall Survival Results of First-Line Docetaxel in Combination with Escalating Doses of Bevacizumab for HER2-Negative Metastatic Breast Cancer

RIBBON 2 — A Phase III Trial of Second-Line Bevacizumab in Combination with Chemotherapy for HER2-Negative Metastatic Breast Cancer

Loading Dose Schedule of Fulvestrant Combined with Anastrozole for the Treatment of Patients with Breast Cancer at First Relapse

High-Dose Fulvestrant for the Treatment of Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

Tumor Biomarker Changes After Presurgical Treatment of Patients with Breast Cancer with High-Dose Fulvestrant and Anastrozole